Co-Principal Investigator, Enhancing First Responder Access to Overdose Treatment in Atlantic County, New Jersey, $2,000,000 over four years, September 2019.
Principal Investigator, Minority AIDS Initiative for High Risk Men of New Jersey, $2,500,000 over five years, August 2019.
Principal Investigator, the New Jersey Opioid Medical Education Program (NJ–OMEP,) $941,582.31 over one year, April 2019 (renewed each year).
Principal Investigator, Southern New Jersey Medication for Addiction Treatment Center of Excellence (SNJ–MATrx–COE), $2,000,000 over one year, March 2019 ($2,000,000 renewed each year).
Principal Investigator, Southern New Jersey Medication for Addiction Treatment Center of Excellence (SNJ–MATrx–COE) Training Amendment, $500,000 over one year, October 2022.
Principal Investigator, Buprenorphine Training Course, SAMHSA, $1,000,000 over one year, March 2019.
Principal Investigator, A Naloxone Training Curriculum for Patients with Opiate Use Disorders to Prevent Fatal Overdose, New Jersey Health Foundation, Grant #PC 46–19, $35,000 over one year, February 2019.
Principal Investigator, New Jersey Collaborative to Improve Access to Overdose Treatment, SAMHSA, $923,340 over five years, August 2018.
Principal Investigator, Opioid Education for Oral Health Workforce and Dental Students Program, HRSA, $500,000 over five years, July 2018.
Principal Investigator, American Osteopathic Association Cost Effectiveness of OMT, $340,468 over two years, May 2018.
Principal Investigator, New Jersey Opioid Medical Education Program (STORI GRANT), $219,561 over two years, January 2018.
Principal Investigator, New Jersey Geriatrics Workforce Enhancement Program—Opioid Supplemental Funding, July 1, 2018.
Principal Investigator, Swedish Lottery Award, $100,000 for a music therapy program, ongoing.
Co–Principal Investigator, Development of a Serum Biomarker–based Approach to Monitor Opioid Adherence and Minimize Substance Misuse in Chronic Pain Management, American Osteopathic Association, $149,763.15, November 1, 2017–October 31, 2019.
Co–Principal Investigator, "To Sleep or Not to Sleep – Are Calcium Sensor Proteins NCALD and S100B Part of the Answer?" Osteopathic Heritage Foundation, $25,000, September 2018–August 2019.
Co–Principal Investigator, "Role of Physicians in Preventing Opioid Overdose in Women" OWH, $100,000, 2018.
Sub-Principal Investigator, "The Effects of Yoga on Persons with HIV–related distal sensory neuropathy" APTA Oncology, $5,000, June 2014.
Principal Investigator, "Relationships of Self–Reported Anxiety, Depression and Pain with Immune Functioning in an HIV Infected Population," Ira DeCamp Foundation, $50,000.
Principal Investigator, "Identification and Treatment of Somatic Dysfunction and its Effects on the Gait Cycle of Patients Post CVA," Osteopathic Heritage Foundation Endowment for Primary Care Research, funded, March 2007.
Principal Investigator, "Osteopathic Manipulative Therapy in the Treatment of Chronic Headache," American Osteopathic Association, $24,500, January 2000, closed.
Principal Investigator, Effect of OMT on the Use of Opioid and Analgesic Medication for Chronic Low Back Pain, American Osteopathic Association, (07–06–562), $95,953, closed.
Principal Investigator, A Phase 2, Randomized, Double–Blind, Placebo–Controlled, Parallel Group, Dose–Ranging, Multi–Center Clinical Trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity in Adults After Stroke or Traumatic Brain Injury, $78,722, April 2019.
Principal Investigator, Integrated OMT/Pain Course and its Influence on Students' Perceptions and Management of Pain Patients, 2017–ongoing.
Principal Investigator, DS–5565–A–312: An Open–label Extension Study of DS–5565 for 52 Weeks in Pain Associated with Fibromyalgia. Daiichi. 01/09/15 ($145,457), closed.
Principal Investigator, The Impact of Music Medicine Therapy on Pain Scale and Quality of Life When Botulinum Toxin (Botox) Injection is Utilized, ongoing.
Principal Investigator, ONU3704: A randomized, double–blind, double–dummy, placebo–controlled, active–controlled, parallel–group, multicenter trial of Oxycodone/Naloxone controlled release tablets (OXN) to assess the analgesic efficacy (compared to placebo) and the management of Opioid–induced Constipation (compared to Oxycodone controlled–release tablets (OXY) in Opioid–experienced subjects with uncontrolled moderate to severe Chronic Low Back Pain and a history of Opioid–induced constipation who require around–the–clock therapy. Purdue Pharma. Closed January 2015. ($118,400)
Principal Investigator, DS5565–A–E309: A Randomized, Double–Blind, Placebo– and Active–Controlled Study of DS–5565 in Subjects with Pain Associated with Fibromyalgia. Daiichi Sankyo. Approved, Pending Activation. December 19, 2014. ($70,440)
Principal Investigator, MRZ 60210/SP/3001: Prospective, double–blind, placebo–controlled, randomized, multicenter study with an open–label extension period to investigate the efficacy and safety of NT 201 in the treatment of post–stroke spasticity of the UPPER limb. Merz Pharmaceuticals GmbH. Closed. 07/19/13–03/19/14 ($116,000)
Principal Investigator, A–tl–52120–169 Dysport 2ml for Treatment of Cervical Dystonia (Double Blind). Ipsen. Enrollment closed. 08/05/2013 ($57,014)
Principal Investigator, A–tl–52120–170 Dysport 2ml for treatment of Cervical Dystonia (Open Label). Ipsen. Enrollment Closed. 08/09/2013 ($72,540)
Principal Investigator, ONU3701: A Randomized, Double–blind, Placebo–controlled, Multicenter Trial with an Enriched Study Design to Assess the Efficacy and Safety of Oxycodone/Naloxone Controlled–release Tablets (OXN) Compared to Placebo in Opioid–experienced Subjects with Moderate to Severe Pain due to Chronic Low Back Pain who Require Around–the–clock Opioid Therapy, Purdue Pharma. Closed. November 9, 2011–January 17, 2013 ($130,190)
Principal Investigator, ONU3705: A randomized, double–blind, double–dummy, placebo–controlled, active–controlled, parallel–group, multicenter trial of Oxycodone/Naloxone controlled release tablets (OXN) to assess the analgesic efficacy (compared to placebo) and the management of Opioid–induced Constipation (compared to Oxycodone controlled–release tablets (OXY) in Opioid–experienced subjects with CONTROLLED moderate to severe Chronic Low Back Pain and a history of Opioid–induced constipation who require around–the–clock therapy. Purdue Pharma. Closed. November 27, 2012–February 5, 2013 ($22,998)
Principal Investigator, 5494–SOIC–12–03: A Multicenter, Randomized, Double–Blind, Placebo–Controlled, Phase 3 Study to Efficacy and Safety of CB–5945 for the Treatment of Opioid–Induced Constipation in Adults Taking Opioid Therapy for Chronic Therapy for Chronic Non–Cancer Pain. Cubist Pharmaceuticals, Inc. Closed. November 2013 – December 23, 2013 ($22,698)
Principal Investigator, 5494–SOIC–12–05: A Multicenter, Randomized, Double–Blind, Placebo–Controlled, Phase 3 Study to Evaluate the Long–Term Safety and Tolerability of CB–5945 for the Treatment of Opioid–Induced Constipation in Adults Taking Opioid Therapy for Chronic Therapy for Chronic Non–Cancer Pain. Cubist Pharmaceuticals, Inc. Closed. August 1, 2013 – November 7, 2013 ($27,095)
Principal Investigator, MRZ 60210/SP/3002: Prospective, double–blind, placebo–controlled, randomized, multicenter study with an open–label extension period to investigate the efficacy and safety of NT 201 in the treatment of post–stroke spasticity of the LOWER limb. Merz Pharmaceuticals GmbH. Enrollment closed March 2, 2012 ($123,400)
Principal Investigator, NMT1077–302, A Phase III, Flexible–Dose Titration Followed by a Randomized Double–Blind Study of Controlled–Release OROS Hydromorphone HC1 (NMED–1077) Compared to Placebo in Patients with Osteoarthritis Pain, Neuromed Pharmaceutical. February 15, 2008 – May 13, 2009 ($28,500) Closed
Principal Investigator, A Multicenter, Randomized, Placebo–Controlled, Double–Blinded Study of the Efficacy and Safety of Lubiprostone in Patients with Opioid–Induced Bowel Dysfunction. Sumcampo Pharmaceuticals. SPI/0211 OBO–06311. Closed. July 9, 2008 – October 22, 2008 ($28,440)
Principal Investigator, A Parallel, Randomized, Double–Blind, Placebo–Controlled, Multicenter Proof of Concept Trial to Assess the Efficacy and Safety of 2 Different Transdermal Doses of Rotigotine in Subject with Signs and Symptoms Associated with Fibromyalgia Syndrome, Schwarz Biosciences. Closed May 24, 2007. ($92,100)
Principal Investigator, Jermyn RT, Principal Investigator, Gupta K, Duffy T, Study C117: A Randomized, Double–Blind, Controlled Study of NGX–4010 for the Treatment of Postherpetic Neuralgia, NeurogesX, Inc. Closed November 2, 2007. ($50,569)
Principal Investigator, A Multicenter Randomized, Double–Blind, Controlled Study of NGX–4010 for the Treatment of Painful HIV–Associated Neuropathy, NeurogesX, Inc., (06/343), $47,130, Closed February 21, 2007
CO–INVESTIGATOR:
Co–Principal Investigator, Effect of DYT2–linked Mutations of HPCA on Calcium Signaling in the NeuroMusculoskeletal System: Dystonia Medical Research Foundation, $129,952; submitted
Co–Principal Investigator, M12–821: Extension Study to Evaluate the Long–Term Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis Associated Pain. Abbvie. Approved, Pending Activation. February 3, 2015 ($131,784)
Co–Principal Investigator, M12–671: A Randomized, Double–Blind, Placebo–Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis–Associated Pain. Abbvie. Open. November 12, 2013 ($149,304)
Co–Principal Investigator, A Multiple–Dose. Non–Randomized, Open–Label, Multicenter Study to Evaluate the Long–Term Safety and Effectiveness of EN3267 in the Treatment of Breakthrough Pain in Cancer Patients, Endo. Closed. September 17, 2008 – January 22, 2009 ($96,970)
